Clinical Trial Update: Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing epirubicin versus no epirubicin in patients with TOP2A-normal early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Epirubicin (epirubicin)

Snippet

Sponsor: Danish Breast Cancer Cooperative Group | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED